biotin Side Effects
Also known as: Vitamin B7
Analysis of 29,879 adverse event reports submitted to the FDA from 2004 to 2025.
Total Reports
29,879
Death-Related
911
3.0% of reports
Hospitalizations
5,552
18.6% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 911 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 497 |
| OFF LABEL USE | 121 |
| NAUSEA | 118 |
| DYSPNOEA | 111 |
| VOMITING | 108 |
| MULTIPLE ORGAN DYSFUNCTION SYNDROME | 107 |
| SEPSIS | 107 |
| CONSTIPATION | 105 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 104 |
| CONDITION AGGRAVATED | 100 |
| ABDOMINAL DISTENSION | 98 |
| ANAEMIA | 98 |
| ABDOMINAL PAIN | 97 |
| HYPONATRAEMIA | 96 |
| SOMNOLENCE | 94 |
| STRESS | 92 |
| ASCITES | 87 |
| CARDIOGENIC SHOCK | 86 |
| VENTRICULAR FIBRILLATION | 85 |
| APPENDICITIS | 83 |
Reactions in Hospitalization Reports
Top reactions in 5,552 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| FATIGUE | 620 |
| NAUSEA | 585 |
| DYSPNOEA | 500 |
| FALL | 495 |
| DIARRHOEA | 483 |
| PNEUMONIA | 453 |
| PAIN | 421 |
| VOMITING | 388 |
| HEADACHE | 367 |
| DIZZINESS | 344 |
| ASTHENIA | 337 |
| DRUG INEFFECTIVE | 328 |
| URINARY TRACT INFECTION | 321 |
| OFF LABEL USE | 310 |
| ARTHRALGIA | 306 |
| WEIGHT DECREASED | 295 |
| PAIN IN EXTREMITY | 285 |
| PYREXIA | 278 |
| MALAISE | 261 |
| CONSTIPATION | 244 |
Nearby — Related Medications
What the FAERS Data Reveals About biotin Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 29,879 voluntary reports linked to biotin and its brand equivalents (Vitamin B7), spanning 2004 through 2025. Of those, 911 (3.0%) listed death as an outcome and 5,552 (18.6%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 90% were female and 10% male; age distribution skews toward 45-64, with 7,221 reports in that bracket. The single most reported reaction is fatigue with 3,046 submissions, followed by nausea and alopecia.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.